PGO0.F Prostatype Genomics AB (publ)

Healthcare Diagnostics & Research Frankfurt Exchange
0.0044 EUR
Close of Nov 12, 2026
0.0038 0.1410
Market cap
EUR 685K
P/E
-
P/B
6.40x
ROE
-167.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is PGO0.F undervalued?

Graham number

The Graham number of Prostatype Genomics AB (publ) cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Prostatype Genomics AB (publ) fundamental analysis

No fundamental analysis for Prostatype Genomics AB (publ) yet.

Prostatype Genomics AB (publ) stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Prostatype Genomics AB (publ)

Prostatype Genomics AB (publ) manufactures, markets, and sells prognostic gene tests. The company offers a Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, RTqPCR kit, patient database and algorithms, Prostatype Web System (PWS), and tumor stage, as well as calculates the P-score. Its test is based on a database containing prostate cancer patients; and provides decision support for patients and doctor…

Full company profile